Targets and accurately quantifies IgG antibodies against the receptor-binding domain (RBD) in the spike protein of SARS-CoV-2
To be used on the HISCL™-5000 immunoassay analyser
Excellent performance and result quality
The HISCL SARS-CoV-2 S-IgG Assay Kit for HISCL-5000 aims to help healthcare providers in monitoring and analysing temporal immunological profiles of SARS-CoV-2 infection and SARS-CoV-2 vaccine effectiveness in different population groups and areas.
The assay targets IgG antibodies against the receptor-binding domain (RBD) portion situated in the S1 domain of the SARS-CoV-2 spike protein (S-protein), which play an important role in the neutralisation activity of the virus*
Technical specifications
Test technology - chemiluminescence enzyme immunoassay (CLEIA)
Dedicated instrument - automated immunoassay system HISCL-5000
Throughput - 200 tests/h on the HISCL-5000
Expression of results - BAU/mL quantitative (calibrated against WHO international reference standard)
Cut-off value - 20 BAU/mL
Measurement tubes - conical 4-mL sample cup (no barcode possible) or standard sample tube
(13–16 mm diameter, 75–100 mm height) with the option of barcode labelling